Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tscan Therapeutics Inc (NQ: TCRX )

3.190 +0.760 (+31.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tscan Therapeutics Inc

TScan Therapeutics Announces Pricing of $140 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Inc. (NASDAQ: TCRX) Near the Top of Equities by Percentage Gain on 5/9
Via Investor Brand Network
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces CEO Transition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Virtual Investor Event
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.